

Eligibility criteria (postmenopausal, Stage II to III BC)  
90 Patients

Biopsy before  
randomization  
Tumor markers:  
ER- $\alpha$ , ER- $\beta$ , Ki-67

12 protocol violations:  
•8 subjects did not take  
tablets correctly  
•3 subjects did not proceed  
to surgery in time  
•1 hormone analysis

Randomization

Placebo  
N = 29

Anastrozole 1 mg/day  
N = 25

Tamoxifen 20 mg/day  
N = 24

Surgery (after 26 days)

Tumor markers: ER- $\alpha$ , ER- $\beta$ , Ki-67